本帖最后由 老马 于 2013-3-13 13:43 编辑
$ z- h/ \- u" |* `' l) p9 ~/ Y
$ E* N9 E2 V# D7 H% K' l健择（吉西他滨）+顺铂+阿瓦斯汀9 A& t# h) U8 u
Gemzar +Cisplatin + Avastin
) A+ b* `1 Q; I4 d phttp://annonc.oxfordjournals.org/content/21/9/1804.full( ]8 w8 A, u- x
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
; I5 }2 Q" I0 APatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 d% c2 J6 ^, dResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* { v- _. P- b3 J) s( A
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 277)
/ d) H8 w0 G5 ^3 \6 w0 A华为网盘附件：
# ^* G7 |# F3 m4 g& @0 M8 x【华为网盘】ava.JPG% \2 g. X) {1 t6 u* m/ j, E3 f. I
|
显身卡
